Aligos Therapeutics, Inc. (ALGS)

Aligos Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	41.95	37	135.7	81.35	186.82	220.38
Short-Term Investments	57.15	19.94	-	44.48	3.92	23.13
Cash & Short-Term Investments	99.1	56.94	135.7	125.83	190.73	243.51
Cash Growth	32.27%	-58.04%	7.85%	-34.03%	-21.67%	106.96%
Restricted Cash	0.11	0.11	0.07	0.12	0.16	0.56
Other Current Assets	4.23	5.09	5.31	7.6	13.53	5.94
Total Current Assets	103.44	62.14	141.08	133.55	204.42	250.02
Property, Plant & Equipment	5.62	7.33	9.82	12.51	14.97	14.91
Long-Term Investments	-	-	-	-	15.11	-
Other Long-Term Assets	0.71	0.63	0.63	0.63	0.87	0.38
Total Assets	109.76	70.09	151.53	146.69	235.37	265.3
Accounts Payable	4.65	2.57	2.52	4.74	3.02	3.31
Accrued Expenses	13.61	15.56	16.84	16.04	25.39	16.56
Current Portion of Leases	3.56	3.46	3.24	3.14	2.91	2.51
Current Unearned Revenue	0.17	0.15	1.31	9.21	7.64	7.89
Total Current Liabilities	21.99	21.74	23.91	33.13	38.96	30.27
Long-Term Leases	2.5	4.92	7.9	9.43	11.55	10.5
Long-Term Unearned Revenue	-	-	-	0.23	-	4.11
Other Long-Term Liabilities	13.44	72.41	27.64	-	0.13	0.38
Total Liabilities	37.93	99.07	59.45	42.79	50.64	45.26
Common Stock	0.01	0.01	0.01	0	0	0
Additional Paid-In Capital	693.69	588.58	578.33	502.61	487.35	394.96
Retained Earnings	-622.32	-618.01	-486.8	-399.12	-303.07	-174.74
Comprehensive Income & Other	0.46	0.45	0.55	0.4	0.45	-0.19
Total Common Equity	71.83	-28.97	92.08	103.9	184.73	220.04
Shareholders' Equity	71.83	-28.97	92.08	103.9	184.73	220.04
Total Liabilities & Equity	109.76	70.09	151.53	146.69	235.37	265.3
Total Debt	6.07	8.38	11.14	12.57	14.46	13.01
Net Cash (Debt)	93.03	48.56	124.57	113.25	176.28	230.51
Net Cash Growth	41.41%	-61.01%	9.99%	-35.75%	-23.52%	123.07%
Net Cash Per Share	10.50	7.75	48.59	66.31	110.57	576.95
Filing Date Shares Outstanding	6.15	6.11	3.03	1.72	1.71	1.53
Total Common Shares Outstanding	6.15	3.86	3	1.72	1.71	1.52
Working Capital	81.45	40.4	117.18	100.42	165.47	219.74
Book Value Per Share	11.67	-7.50	30.65	60.52	108.18	144.30
Tangible Book Value	71.83	-28.97	92.08	103.9	184.73	220.04
Tangible Book Value Per Share	11.67	-7.50	30.65	60.52	108.18	144.30
Machinery	8.23	8.04	7.91	8.28	7.48	6.23
Construction In Progress	0.16	0	0	0.02	0.02	0.07
Leasehold Improvements	6.1	6.1	6.1	6.09	5.94	5.66

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q